In this conference update video, Profs. Michael Gnant and Giuseppe Curigliano provide key insights from the highly anticipated 19th St. Gallen Breast Cancer Conference (SGBCC) Satellite Symposium, sponsored by Menarini Stemline. 

In this conference update video, Profs. Michael Gnant and Giuseppe Curigliano provide key insights from the highly anticipated 19th St. Gallen Breast Cancer Conference (SGBCC) Satellite Symposium, sponsored by Menarini Stemline. 

 

Key topics included: 

  • Defining recurrence risk in high- vs low-risk groups 
  • Review of current treatment guidelines 
  • Ongoing clinical trials evaluating oral SERDs in the adjuvant early breast cancer setting 

 

Clinical takeaways

  • Risk assessment enables personalized treatment approaches, optimizing therapeutic outcomes 
  • High-risk patients exhibit significantly lower invasive disease-free survival than intermediate/low-risk groups, underscoring the need for enhanced treatment strategies
  • Adjuvant ET intensification with CDK4/6 inhibitors has shown clinical benefit; however, emerging resistance remains a challenge, contributing to disease recurrence
  • Oral SERDs have shown evidence of superior efficacy over SOC in metastatic settings, particularly in the presence of ESR1-mut and are now being explored in early-stage disease as either an upfront or switch treatment strategy  
  • Elacestrant is the only oral SERD with agonistic properties being investigated as a switch strategy in a “pure high-risk population” following demonstration of CCCA rate reduction, substantial Ki-67 suppression, and activity in ESR1 wild-type breast cancer  

Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast and Colorectal Cancer Study Group. He has been co-chairing and hosting St. Gallen International Consensus Panel for Early Breast Cancer since 2015 and is involved in many scientific societies including ASCO, AACR, ACS, BIG, EORTC, ESSO, EUSOMA, and UICC.​

Prof. Michael Gnant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, EPG Health (IQVIA), Menarini Stemline, MSD, Novartis, Pierre Fabre, and Veracyte​

Director of the Early Drug Development Division and Co-Chair for the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milan, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milan. Moreover, he is a member of the Italian National Health Council, serving as an adviser to the Ministry of Health for cancer policy issues.

Prof. Giuseppe Curigliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Exact Sciences, Menarini, Merck, Novartis, Pfizer, Roche, Ellipsis, Astellas, Blueprint Medicines, BMS, Kymab, Philogen, Relay Therapeutics and Sanofi​

Programme summary
Watch the video now
Share this programme
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
Supporter Acknowledgement
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
I agree that this programme:

Was valuable to me

1/3

Other programmes of interest

video Video
Oncology 
The patient perspective: Living with NSCLC driven by a rare alteration

What to know, what to expect, and where to find support

Experts
Marcia Horn
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
BRAF Bombers PD-L1 Amplifieds MET crusaders
  • clock 8 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim.
animated-video Animated Video
Oncology 
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma

Optimising 1st and 2nd line treatment

Experts
Prof. Eileen O'Reilly, Prof. Efrat Dotan
Endorsed by
ICAN international cancer advocacy network DiCE PanCAN
National Pancreas Foundation
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA.
podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
podcast Podcast
Oncology 
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

Experts' insights on treatment strategies in ER+ metastatic breast cancer settings

Experts
Dr Aditya Bardia, Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
eks
Experts Knowledge Share Video
Oncology 
HER2 testing: The evolving role of immunohistochemistry (IHC)

Best practices and interpretation of results in lung and ovarian cancer 

Experts
Prof. Fernando López-Ríos, MD, PhD, Prof. Christian Rolfo, Prof. Charlie Gourley
Endorsed by
Exon20group ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 77 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.